Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFONSECA, Guilherme Wesley Peixoto Da
dc.contributor.authorDWORATZEK, Elke
dc.contributor.authorEBNER, Nicole
dc.contributor.authorHAEHLING, Stephan Von
dc.date.accessioned2020-12-16T14:56:09Z
dc.date.available2020-12-16T14:56:09Z
dc.date.issued2020
dc.description.abstractIntroduction Skeletal muscle wasting is a frequent clinical problem encountered in patients with chronic diseases. Increased levels of inflammatory markers play a role in the imbalance between muscle protein synthesis and degradation. Although testosterone has long been proposed as a treatment for patients with muscle wasting, undesirable side effects have raised concerns about prostatic hypertrophy in men as well as virilization in women. Selective androgen receptor modulators (SARMs) have demonstrated similar results like testosterone at improving lean body mass (LBM) with less side effects on androgen-dependent tissue. Areas covered This review outlines the ongoing clinical development in the field of SARMs and their effectiveness in improving body composition and physical function. The included articles were collected at pubmed.gov and analyzed integrally. Expert opinion There is an unmet clinical need for safe and effective anabolic compounds such as SARMs. Despite the effect on LBM shown by SARMs in phase II clinical trials, results on improved physical function and muscle strength are still lacking and long-term outcomes have to be assessed in these patients. Moreover, there is a need to determine the effect of resistance exercise training and protein intake associated with SARMs in the treatment of patients with muscle wasting.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brazil (CAPES)CAPES [001]
dc.description.sponsorshipGerman Center for Cardiovascular Research (DZHK)
dc.identifier.citationEXPERT OPINION ON INVESTIGATIONAL DRUGS, v.29, n.8, p.881-891, 2020
dc.identifier.doi10.1080/13543784.2020.1777275
dc.identifier.eissn1744-7658
dc.identifier.issn1354-3784
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/38491
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTDeng
dc.relation.ispartofExpert Opinion on Investigational Drugs
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright TAYLOR & FRANCIS LTDeng
dc.subjectAndrogen receptoreng
dc.subjectcachexiaeng
dc.subjectmuscle wastingeng
dc.subjectsarcopeniaeng
dc.subjectselective androgen receptor modulatorseng
dc.subjecttestosteroneeng
dc.subject.otherlean body-masseng
dc.subject.otherchronic heart-failureeng
dc.subject.othercell lung-cancereng
dc.subject.otherdouble-blindeng
dc.subject.otherskeletal-muscleeng
dc.subject.otherphysical functioneng
dc.subject.otherolder meneng
dc.subject.otherphase-iieng
dc.subject.othertestosteroneeng
dc.subject.othercachexiaeng
dc.subject.wosPharmacology & Pharmacyeng
dc.titleSelective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trialseng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryAlemanha
hcfmusp.affiliation.countryisode
hcfmusp.author.externalDWORATZEK, Elke:Charite Univ Med Berlin, Inst Gender Med, Berlin, Germany; Free Univ Berlin, Berlin, Germany; Berlin Inst Hlth, Berlin, Germany; Helmholtz Assoc, Max Delbrueck Ctr Mol Med MDC, Deptt Muscle Physiol, Berlin, Germany; German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany
hcfmusp.author.externalEBNER, Nicole:Univ Gottingen, Dept Cardiol & Pneumol, Med Ctr, D-37075 Gottingen, Germany; German Ctr Cardiovasc Res DZHK, Partner Site Gottingen, Gottingen, Germany
hcfmusp.author.externalHAEHLING, Stephan Von:Univ Gottingen, Dept Cardiol & Pneumol, Med Ctr, D-37075 Gottingen, Germany; German Ctr Cardiovasc Res DZHK, Partner Site Gottingen, Gottingen, Germany
hcfmusp.citation.scopus31
hcfmusp.contributor.author-fmusphcGUILHERME WESLEY PEIXOTO DA FONSECA
hcfmusp.description.beginpage881
hcfmusp.description.endpage891
hcfmusp.description.issue8
hcfmusp.description.volume29
hcfmusp.origemWOS
hcfmusp.origem.pubmed32476495
hcfmusp.origem.scopus2-s2.0-85087115697
hcfmusp.origem.wosWOS:000545711500001
hcfmusp.publisher.cityABINGDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceAikawa K, 2015, BIOORGAN MED CHEM, V23, P2568, DOI 10.1016/j.bmc.2015.03.032eng
hcfmusp.relation.referenceAllan G, 2008, J STEROID BIOCHEM, V110, P207, DOI 10.1016/j.jsbmb.2007.10.012eng
hcfmusp.relation.referenceAllan GF, 2007, ENDOCRINE, V32, P41, DOI 10.1007/s12020-007-9005-2eng
hcfmusp.relation.referenceArgiles JM, 2015, CURR OPIN PHARMACOL, V22, P100, DOI 10.1016/j.coph.2015.04.003eng
hcfmusp.relation.referenceBasaria S, 2001, J CLIN ENDOCR METAB, V86, P5108, DOI 10.1210/jc.86.11.5108eng
hcfmusp.relation.referenceBasaria S, 2015, JAMA-J AM MED ASSOC, V314, P570, DOI 10.1001/jama.2015.8881eng
hcfmusp.relation.referenceBasaria S, 2013, J GERONTOL A-BIOL, V68, P87, DOI 10.1093/gerona/gls078eng
hcfmusp.relation.referenceBauer J, 2019, J CACHEXIA SARCOPENI, V10, P956, DOI 10.1002/jcsm.12483eng
hcfmusp.relation.referenceBhattacharya I, 2016, CLIN THER, V38, P1401, DOI 10.1016/j.clinthera.2016.03.025eng
hcfmusp.relation.referenceBlanque R, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-291eng
hcfmusp.relation.referenceCaminiti G, 2009, J AM COLL CARDIOL, V54, P919, DOI 10.1016/j.jacc.2009.04.078eng
hcfmusp.relation.referenceChekler ELP, 2014, J MED CHEM, V57, P2462, DOI 10.1021/jm401625beng
hcfmusp.relation.referenceChisamore MJ, 2016, J STEROID BIOCHEM, V163, P88, DOI 10.1016/j.jsbmb.2016.04.007eng
hcfmusp.relation.referenceClark RV, 2017, BRIT J CLIN PHARMACO, V83, P2179, DOI 10.1111/bcp.13316eng
hcfmusp.relation.referenceCoats AJS, 2016, J CACHEXIA SARCOPENI, V7, P355, DOI 10.1002/jcsm.12126eng
hcfmusp.relation.referenceCoss CC, 2016, INVEST NEW DRUG, V34, P458, DOI 10.1007/s10637-016-0353-8eng
hcfmusp.relation.referenceCozzoli A, 2013, PHARMACOL RES, V72, P9, DOI 10.1016/j.phrs.2013.03.003eng
hcfmusp.relation.referenceCrawford J, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0522-0eng
hcfmusp.relation.referenceCrawford J, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9618eng
hcfmusp.relation.referenceCurrow D, 2017, ANN ONCOL, V28, P1949, DOI 10.1093/annonc/mdx192eng
hcfmusp.relation.referenceDalton JT, 2011, J CACHEXIA SARCOPENI, V2, P153, DOI 10.1007/s13539-011-0034-6eng
hcfmusp.relation.referenceDalton JT, 1998, BIOCHEM BIOPH RES CO, V244, P1, DOI 10.1006/bbrc.1998.8209eng
hcfmusp.relation.referenceDobs AS, 2013, LANCET ONCOL, V14, P335, DOI 10.1016/S1470-2045(13)70055-Xeng
hcfmusp.relation.referenceDubois V, 2015, ENDOCRINOLOGY, V156, P4522, DOI 10.1210/en.2015-1479eng
hcfmusp.relation.referenceEbner N, 2019, J CACHEXIA SARCOPENI, V10, P218, DOI 10.1002/jcsm.12408eng
hcfmusp.relation.referenceEbner N, 2018, J CACHEXIA SARCOPENI, V9, P176, DOI 10.1002/jcsm.12290eng
hcfmusp.relation.referenceFulster S, 2013, EUR HEART J, V34, P512, DOI 10.1093/eurheartj/ehs381eng
hcfmusp.relation.referenceGao WQ, 2005, ENDOCRINOLOGY, V146, P4887, DOI 10.1210/en.2005-0572eng
hcfmusp.relation.referenceGao WQ, 2005, CHEM REV, V105, P3352, DOI 10.1021/cr020456ueng
hcfmusp.relation.referenceGarber K, 2016, NAT BIOTECHNOL, V34, P458, DOI 10.1038/nbt.3557eng
hcfmusp.relation.referenceGTx I, 2018, GTX ANNOUNCED NEW DAeng
hcfmusp.relation.referenceHamann LG, 1999, J MED CHEM, V42, P210, DOI 10.1021/jm9806648eng
hcfmusp.relation.referenceHanada K, 2003, BIOL PHARM BULL, V26, P1563, DOI 10.1248/bpb.26.1563eng
hcfmusp.relation.referenceHeemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019eng
hcfmusp.relation.referenceHOLMANG S, 1993, PROSTATE, V23, P99, DOI 10.1002/pros.2990230203eng
hcfmusp.relation.referenceIba H, 2019, BIOL PHARM BULL, V42, P2009, DOI 10.1248/bpb.b19-00499eng
hcfmusp.relation.referenceJayaraman A, 2014, ENDOCRINOLOGY, V155, P1398, DOI 10.1210/en.2013-1725eng
hcfmusp.relation.referenceJones A, 2010, ENDOCRINOLOGY, V151, P3706, DOI 10.1210/en.2010-0150eng
hcfmusp.relation.referenceKato K, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03138eng
hcfmusp.relation.referenceKim J, 2013, XENOBIOTICA, V43, P993, DOI 10.3109/00498254.2013.788233eng
hcfmusp.relation.referenceKomrakova M, 2020, CALCIFIED TISSUE INT, V106, P147, DOI 10.1007/s00223-019-00613-1eng
hcfmusp.relation.referenceKrishnan V, 2018, ANDROLOGY-US, V6, P455, DOI 10.1111/andr.12479eng
hcfmusp.relation.referenceKuki A, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1370-6eng
hcfmusp.relation.referenceLiu P, 2017, MATURITAS, V103, P16, DOI 10.1016/j.maturitas.2017.04.007eng
hcfmusp.relation.referenceMiller CP, 2011, ACS MED CHEM LETT, V2, P124, DOI 10.1021/ml1002508eng
hcfmusp.relation.referenceMiner JN, 2007, ENDOCRINOLOGY, V148, P363, DOI 10.1210/en.2006-0793eng
hcfmusp.relation.referenceMorimoto M, 2017, ONCOL LETT, V14, P8066, DOI 10.3892/ol.2017.7200eng
hcfmusp.relation.referenceNarayanan R, 2018, MOL CELL ENDOCRINOL, V465, P134, DOI 10.1016/j.mce.2017.06.013eng
hcfmusp.relation.referenceNegro-Vilar A, 1999, J CLIN ENDOCR METAB, V84, P3459, DOI 10.1210/jc.84.10.3459eng
hcfmusp.relation.referenceNeil D, 2018, J CLIN ENDOCR METAB, V103, P3215, DOI 10.1210/jc.2017-02644eng
hcfmusp.relation.referenceNique F, 2012, J MED CHEM, V55, P8236, DOI 10.1021/jm300281xeng
hcfmusp.relation.referenceOstrowski J, 2007, ENDOCRINOLOGY, V148, P4, DOI 10.1210/en.2006-0843eng
hcfmusp.relation.referencePapanicolaou DA, 2013, J NUTR HEALTH AGING, V17, P533, DOI 10.1007/s12603-013-0335-xeng
hcfmusp.relation.referenceReiter M, 2010, HORM MOL BIOL CLIN I, V1, P73, DOI 10.1515/HMBCI.2010.007eng
hcfmusp.relation.referenceRyan AM, 2019, NUTRITION, V67-68, DOI 10.1016/j.nut.2019.06.020eng
hcfmusp.relation.referenceSchmidt A, 2010, J BIOL CHEM, V285, P17054, DOI 10.1074/jbc.M109.099002eng
hcfmusp.relation.referenceSheffield M, 2014, STEINER RESIGNS GTXeng
hcfmusp.relation.referenceSingam ERA, 2019, J PHYS CHEM B, V123, P7657, DOI 10.1021/acs.jpcb.9b05654eng
hcfmusp.relation.referenceSmith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023eng
hcfmusp.relation.referenceSolheim TS, 2018, BMJ SUPPORT PALLIAT, V8, P258, DOI 10.1136/bmjspcare-2017-001440eng
hcfmusp.relation.referenceTemel JS, 2016, LANCET ONCOL, V17, P519, DOI 10.1016/S1470-2045(15)00558-6eng
hcfmusp.relation.referenceThevis M, 2018, MOL CELL ENDOCRINOL, V464, P34, DOI 10.1016/j.mce.2017.01.040eng
hcfmusp.relation.referenceThevis M, 2018, EUR J MASS SPECTROM, V24, P145, DOI 10.1177/1469066717731228eng
hcfmusp.relation.referenceThevis M, 2011, DRUG TEST ANAL, V3, P1, DOI 10.1002/dta.245eng
hcfmusp.relation.referenceTravison TG, 2011, J GERONTOL A-BIOL, V66, P1090, DOI 10.1093/gerona/glr100eng
hcfmusp.relation.referenceURMAN B, 1991, OBSTET GYNECOL, V77, P595eng
hcfmusp.relation.referenceVajda EG, 2009, J BONE MINER RES, V24, P231, DOI [10.1359/jbmr.081007, 10.1359/JBMR.081007]eng
hcfmusp.relation.referenceVajda EG, 2009, J PHARMACOL EXP THER, V328, P663, DOI 10.1124/jpet.108.146811eng
hcfmusp.relation.referenceViking T, 2014, VIKING SIGNS BROAD Leng
hcfmusp.relation.referenceWu D, 2006, DRUG METAB DISPOS, V34, P483, DOI 10.1124/dmd.105.006643eng
hcfmusp.relation.referenceYu ZY, 2017, CLIN CANCER RES, V23, P7608, DOI 10.1158/1078-0432.CCR-17-0670eng
hcfmusp.relation.referenceZierau O, 2019, J STEROID BIOCHEM, V189, P81, DOI 10.1016/j.jsbmb.2019.02.014eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationb9f224a0-2ecb-4e05-8c7d-5005cbcdecb4
relation.isAuthorOfPublication.latestForDiscoveryb9f224a0-2ecb-4e05-8c7d-5005cbcdecb4
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros